AGCO Power: Forestry Machines Need Purpose-Built Off-Road Engines – Not Compromises
8.9.2026 09:00:00 EEST | Business Wire | Press release
Modern forestry machines work in some of the most demanding conditions in the off-road world. Harvesters and forwarders operate far from workshops, under rapidly changing loads and in environments where uptime, fuel efficiency and serviceability have a direct impact on productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260907908774/en/
Forestry applications place very different demands on an engine than on-road applications do,” says Juha Tervala, Managing Director at AGCO Power. Juha Tervala and Andreas Eurs, Product Manager at long-standing partner Logset, are pictured presenting Logset’s new 8H GTE 4.0 Hybrid harvester, powered by an AGCO Power engine.
For AGCO Power, the starting point is clear: a forestry machine needs an engine designed for demanding off-road applications.
“Forestry applications place very different demands on an engine than on-road applications do. The engine must respond instantly to changing loads, work seamlessly with the machine’s hydraulic and control systems, and keep it productive in conditions where downtime is costly,” says Juha Tervala, Managing Director at AGCO.
AGCO Power will present its modern diesel engines for demanding off-road applications at INTERFORST 2026, held at Messe München on 15–18 October. Visitors can find AGCO Power in the Systems & Components area, booth B6.141.
The CORE engine family combines fast load response, fuel efficiency, practical serviceability and long-term reliability. In forestry applications, these are not just technical characteristics, but factors that directly affect machine productivity and operating costs.
Designed for demanding off-road work
Forestry places very specific demands on an engine. In a harvester, the load changes rapidly as the head feeds, delimbs and cuts timber. In a forwarder, the engine must deliver controlled power when moving heavy loads over uneven terrain, slopes and soft ground.
In these conditions, reliable operation is not only about power and torque. The engine must also maintain dependable lubrication and performance when the machine is working on inclines or in tilted positions, as forestry machines often operate on uneven ground for extended periods.
“Performance in forestry is created by the whole machine. The engine, hydraulics, software and serviceability must be designed as one integrated system,” says Jarno Ratia, Director of Product Management of AGCO Power.
The CORE platform is designed around high torque, low engine speeds, efficiency and adaptability to different applications. Its architecture also supports future powertrain technologies such as hybridization and alternative fuels.
The modular CORE family currently includes three engine options for different power requirements: the four-cylinder CORE50, producing up to 165 kW and 950 Nm; the six-cylinder CORE75, producing up to 250 kW and 1,450 Nm; and the latest variant, CORE80, rated at 252 kW with maximum torque of 1,680 Nm.
Easy serviceability supports uptime
In forestry, serviceability is a direct part of productivity. Machines often operate long hours and far from service locations, so routine maintenance needs to be straightforward, and downtime kept to a minimum.
“Good serviceability supports both people and productivity. In cold, dark or remote conditions, a well-designed service layout makes routine maintenance more ergonomic and efficient, while helping the machine return to productive operation sooner,” says Ratia.
The technical architecture of the engine also affects serviceability and reliability. CORE engines achieve low emissions without exhaust gas recirculation, or EGR, and without two-stage turbocharging. This supports a simpler engine layout and reduces the number of components in the system.
Proven fuel efficiency in independent DLG PowerMix testing*
Fuel efficiency, demonstrated by independent DLG PowerMix tests (test reports 7547, 7552, 7435 and 7599), is an important advantage of AGCO Power’s modern CORE engines. Although DLG PowerMix is a tractor test rather than a forestry-machine test, the results provide independent evidence of the efficiency of the CORE engine platform across different load points and engine-speed ranges.
The results also demonstrate the importance of powertrain integration. Fuel efficiency is not determined by the engine alone, but by how the engine, transmission, hydraulics and software work together in the complete machine.
“Lower fuel consumption immediately affects operating costs. But efficiency cannot come at the expense of response, durability or uptime. That balance is where AGCO Power’s off-road experience makes the difference,” says Ratia.
AGCO Power at INTERFORST
International Key Trade Fair for Forestry and Forest
Messe München, 15–18 October 2026
Systems & Components
Booth B6.141
About AGCO Power
AGCO Power is one of the world’s leading developers and manufacturers of engines for off-road machines. We produce engines for well-known tractor brands such as Fendt, Valtra, and Massey Ferguson. In addition to these, AGCO Power engines are used in other off-road machines, including forestry equipment. Production facilities are located in Finland, China, Brazil, and Argentina. The Linnavuori plant has been operating for over 80 years and is a subsidiary of AGCO Corporation. www.agcopower.com.
About AGCO
AGCO (NYSE: AGCO) is a global leader in agricultural machinery and precision agriculture technologies. Driven by a Farmer-First strategy, AGCO delivers value through its differentiated leading brands, Fendt™, Massey Ferguson™, PTx™ and Valtra™. AGCO’s high-performance equipment and smart farming solutions, including brand-agnostic retrofit technologies and autonomous offerings, empower farmers to drive productivity while sustainably feeding the world. For more information, visit www.agcocorp.com.
*Source material for DLG PowerMix tests
- Fendt 620 Vario with the CORE50 engine, DLG Test Report 7547
- Fendt 724 Vario Gen7.1 with the CORE75 engine, DLG Test Report 7552
- Fendt 728 Vario Gen7 with the CORE75, DLG Test Report 7435
- Fendt 832 Vario with the CORE80 engine, DLG Test Report 7599
View source version on businesswire.com: https://www.businesswire.com/news/home/20260907908774/en/
Contacts
For more information and interview requests:
Communications Manager Vilja Pylsy, vilja.pylsy@agcocorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom